Purple Biotech: What The CM24 And NT219 Write-Down Really Means
The USD 20.482 million write-down in 2025 does not mean CM24 and NT219 lost all clinical value. It does mean Purple Biotech stopped carrying them as internally funded balance-sheet assets, so any future value now has to arrive through a partner, dedicated investment, or data strong enough to force the next study.
Where The Main Article Stopped, And What This Follow-Up Is Isolating
The main article already argued that Purple Biotech's cash bought time around IM1240 while the older assets had stopped being a comfortable balance-sheet anchor. This follow-up isolates the second point: what the CM24 and NT219 write-down actually says, and why its meaning runs deeper than the accounting line itself.
The short answer is that the write-down does not say the science went to zero. It says the company stopped assigning balance-sheet value to those two assets based on a development plan it is willing to finance internally. Once further development of CM24 and NT219 is explicitly framed as dependent on partnering or sufficient investment, they stop looking like assets that carry the balance sheet and start looking like off-balance-sheet options waiting for outside validation.
This was also not a fresh cash burn event. Purple recorded a total USD 20.482 million write-down on TyrNovo and FameWave in 2025, but the same amount was added back in cash flow as a non-cash adjustment. Anyone reading the write-down as cash that left the company in 2025 is missing the point, and anyone treating it as meaningless housekeeping is missing the point too. The signal is not primarily about cash. It is about strategy.
What Was Actually Written Down
At year-end 2024, Purple still carried USD 27.842 million of intangible assets on the balance sheet: USD 6.172 million tied to TyrNovo, meaning NT219, another USD 14.310 million tied to FameWave, meaning CM24, and USD 7.360 million tied to Immunorizon. By year-end 2025, only the Immunorizon asset remained. The two legacy assets were fully impaired.
| Layer | End 2024, USD millions | 2025 change | End 2025, USD millions | What it means |
|---|---|---|---|---|
| TyrNovo / NT219 | 6.172 | Full write-down | 0 | The balance sheet no longer assigns internal value to this asset |
| FameWave / CM24 | 14.310 | Full write-down | 0 | Here too, value moved from the balance sheet to optionality |
| Immunorizon / CAPTN-3 | 7.360 | No write-down | 7.360 | This is the only IPR&D asset still carried |
| Total intangible assets | 27.842 | (20.482) | 7.360 | The legacy-asset layer almost disappeared |
That is the difference between a technical write-down and a real reset in the company read. Purple says the impairment followed a reassessment of the development programs and of the expected future economic benefits. It valued the IPR&D assets through discounted cash flow, using an 18% discount rate, and ran sensitivity around probability of success and the discount rate. Inside that exact same framework, CM24 and NT219 went to zero while Immunorizon stayed at USD 7.360 million.
So this was not a blanket haircut across the whole pipeline. It was a clear split between one asset management still believes it can justify on the books and two assets the company is no longer willing to pre-credit on the balance sheet.
The Write-Down Is Accounting, But The Message Is Strategic
In the income statement, the impairment made 2025 look much worse. Operating loss reached USD 27.458 million, and USD 20.482 million of that was impairment loss. In the cash flow statement, the picture is completely different: annual loss was USD 26.492 million, but USD 20.482 million came back as a non-cash adjustment, leaving operating cash outflow at USD 5.656 million.
That matters because the write-down does not tell us how much fresh cash Purple spent on CM24 and NT219 during 2025. It tells us the company no longer presents those programs as something that can support carried value from the existing balance sheet. The right read is not "the assets disappeared." The right read is "their value now has to be re-earned from the outside."
The language around the programs points in the same direction. Purple explicitly says further development of CM24 and NT219 is planned only upon partnering or obtaining sufficient investment for the next study, and both assets are already framed as partnership opportunities rather than as fully internally driven development programs.
What Optionality Still Remains
The impairment did not turn CM24 and NT219 into scientific zeros. It turned them into options that require external validation. And it matters that the two options are not identical.
CM24
CM24 still rests on data the company itself highlights. Purple presents a randomized Phase 2 study in second-line PDAC with better outcomes than control across all the main efficacy endpoints: ORR of 25% versus 6.7%, DCR of 62.5% versus 46.7%, a 19% reduction in risk of death, and a 25% reduction in risk of progression or death. That does not look like a program that became irrelevant.
But it also does not look like a broad internally funded plan. The opposite is true. The next step is already framed around a biomarker-selected population. Purple also shows stronger results in subgroups defined by serum CEACAM1, MPO, or tumor CEACAM1 expression, including a 78% reduction in risk of death and a 95% reduction in risk of progression or death. That matters because it explains what remains of the asset: not a broad all-comer program, but a targeted biomarker story that still needs a partner or capital to become the next study.
The timeline makes that even clearer. CM24 is presented as a partnership opportunity, and the next step is described as a Phase 2b that would start only upon partnership. So the real meaning of the write-down in CM24 is not "no value." It is there is still a signal here, but there is no internal balance-sheet capital today that is ready to pay for the confirmatory next step.
NT219
NT219 sits in a slightly different place. It too was written down to zero as TyrNovo IPR&D, so the balance sheet is no longer carrying internal value here either. But this program still has a nearer validation path: a Phase 2 study in recurrent and/or metastatic head and neck cancer was initiated in June 2025, and Purple points to interim data during 2026.
Again, the option is backed by data rather than by an empty story. Purple shows 16 evaluable patients in the combination arm, ORR of 25% and DCR of 62.5% across dose levels, plus a biomarker signal in activated pIGF1R and pSTAT3 that was observed between responders and non-responders and then checked again in the 100 mg/kg cohort. NT219 is also framed as one of two Phase 2 assets with positive data available for partnership.
But the constraint is still the same constraint: development beyond the current study depends on a partner or sufficient investment. So NT219 is not an asset that currently supports accounting value. It is an option that now has to prove itself through the 2026 readout strongly enough to attract the capital or the partner needed for the next step. In that sense, NT219 looks more alive than CM24 in the near term because it still has an interim readout ahead, but it is no less dependent on outside validation.
| Program | What is already there | What is still missing | What would restore practical value |
|---|---|---|---|
| CM24 | Phase 2 data with consistent improvement, plus a stronger biomarker-selected subgroup signal | Funding for the next study and a partner willing to underwrite the signal | Partnership or investment that opens the Phase 2b path |
| NT219 | An active Phase 2 study, 2026 interim data ahead, and a biomarker signal in responders | Proof that the upcoming readout is strong enough to justify continuation | A sharp interim readout that converts into a partner or dedicated financing |
Conclusion
This is therefore a write-down of a category, not just of a number. CM24 and NT219 did not disappear from the pipeline, but they moved from the shelf of "assets the balance sheet still gives credit to" to the shelf of "options that need outside validation." Anyone reading 2025 as if the company abandoned both projects is missing the clinical and biomarker signals Purple still shows. Anyone reading 2025 as if nothing really changed is missing the more important point: from here, value has to arrive through a partner, dedicated investment, or a data readout strong enough to force the next step.
In other words, the market should not only ask whether there is still value left in CM24 and NT219. It should ask who is willing to fund the next study, and on what terms. Until there is a strong answer to that question, the balance sheet has already taken its side.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.